Can the formula be customized?

Yes, the active ingredients can be customized based on client requirements.

What is the shelf life of the product?

The product has a shelf life of 2 years.

What packaging options are available?

Available in 1kg/bag and 25kg/bag packaging.

Outstanding Mixed Probiotics Powder for Animal GMP ISO Standard

Name: Outstanding Mixed Probiotics Powder for Animal GMP ISO Standard
Brand: Henan Muxiang Biological Co., Ltd.
SKU: 1986550922

Henan, ChinaHenan Muxiang Biological Co., Ltd.

US$790.00-900.00

1 Ton

Sample price:US$1.00/kg.Request sample

Product profile

Customization

Available

Certification

ISO, ISO

Shape

Powder

Model NO.

Powder

Active Ingredient

Bacillus Subtilis, Clostridium Butyricum

Function

Bacteriostasis Growth Promoter

Type

Functional Additives

Transport Package

Bacillus Subtilis, Clostridium Butyricum

Trademark

Moosun

Origin

China

HS Code

2309901000

Production Capacity

500t/Month

Key features

ISO Certified Quality: Meets ISO standards for production and safety assurance.

Dual Probiotic Formula: Contains Bacillus subtilis and Clostridium butyricum for gut health.

Curcumin Enriched: Rich in turmeric powder for anti-inflammatory and antioxidant benefits.

Growth Promotion: Improves feed utilization and promotes livestock growth.

Antibiotic Reduction: Helps reduce antibiotic use while maintaining animal immunity.

Extended Shelf Life: Guaranteed shelf life of 2 years when stored properly.

Customizable Formula: Active ingredients can be customized to meet specific needs.

OEM/ODM Support: Full OEM and ODM services available for brand partners.

Company profile

Henan Muxiang Biological Co., Ltd.

Henan, China

CertifiedBusiness Type: Manufacturer/Factory & Trading Company CertifiedR&D Capacity: ODM Service Available & OEM Service AvailableExport Year: 2016-02-01 CertifiedNearest Port: Shanghai Port, Qingdao PortAverage Response Time: ≤10.16h CertifiedTerms of Payment: LC, T/T, D/P, etc.

AI-Powered supplier vetting

SummaryHenan Muxiang Biological Co., Ltd. is a China-based limited-company factory established in 2004, with 360 employees and operations in veterinary pharmaceuticals and animal-health products. The supplier reports seven pharmaceutical production lines, eight vaccine production lines, first-class production and inspection equipment, GMP management, ISO9001:2015 certification, and ISO/CNAS laboratory certification. Its R&D resources include more than 40 core personnel, over 30 of whom hold doctoral or master's degrees, while 21–30 quality-control staff are reported. The company exports to multiple global regions, has self-operated import and export rights, and states a one-month order-fulfillment period in both peak and off-peak seasons. Evidence supports capabilities in certification, innovation, production, and international operations. However, the provided information does not sufficiently establish after-sales service performance, financial credibility, customization execution, or specific customer cases.

Supplier typeThe supplier is identified as a limited company and a factory in the manufacturing industry, with its operating location in Henan, China. This indicates a direct manufacturing entity rather than only a trading or intermediary business.

CertificationsThe supplier reports a systematic GMP management system, ISO/CNAS laboratory international certification, and an ISO9001:2015 certificate. These stated certifications and quality systems provide explicit evidence of formal quality-management capability.

R&D capabilityThe supplier reports more than 40 core R&D personnel, including over 30 doctors or master's degree graduates, 20 years of preparation-technology experience among R&D engineers, and advanced R&D platforms such as a National Enterprise Technology Center, National Postdoctoral Research Station, and Academician Workstation. It also reports improving herbal active-ingredient extraction by more than 30% versus a traditional process, supporting a strong stated innovation profile.

Production capacityThe supplier reports seven pharmaceutical production lines and eight vaccine production lines, first-class production and inspection equipment, six production lines in a separate operational data field, and one-month order fulfillment in both peak and off-peak seasons. Although the line-count figures are not fully consistent across the slices, the evidence clearly supports substantial pharmaceutical and vaccine manufacturing capability.